Anti-gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) Monoclonal Antibody

By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This monoclonal antibody reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This monoclonal antibody labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation.

Melanocyte protein PMEL; ME20-M; ME20M; Melanocyte protein Pmel 17; Melanocytes lineage-specific antigen GP100; Melanoma-associated ME20 antigen; P1; P100; Premelanosome protein; Silver locus protein homolog; M-alpha;95 kDa melanocyte-specific secreted glycoprotein; P26; Secreted melanoma-associated ME20 antigen; ME20-S; ME20S; M-beta; PMEL; D12S53E, PMEL17, SILV

Preferentially expressed in melanomas. Some expression was found in dysplastic nevi. Not found in normal tissues nor in carcinomas. Normally expressed at low levels in quiescent adult melanocytes but overexpressed by proliferating neonatal melanocytes and during tumor growth.

Amino Acid Metabolism, Amino Acids, Cancer, Cell Type Markers, Metabolic Signaling Pathways, Metabolism, Pathways and Processes, Signal Transduction, Tumor Associated, Tumor Immunology, Tumor-Associated Antigens

Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. .

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.